What prior authorization criteria does Medica use for Xifaxan (rifaximin)?
Medica’s commercial prior authorization (PA) criteria for Xifaxan (rifaximin) typically require that the prescription match an approved FDA indication for rifaximin and that the patient meets standard payer conditions (for example, diagnosis-specific documentation and confirmation that the medication is being used at the correct dose for that indication).
However, Medica’s exact PA checklist can vary by product line and plan, and the publicly available description of criteria is often not complete enough to reproduce verbatim “if/then” rules for every commercial plan.
What diagnosis does Medica usually require for rifaximin PA?
For commercial PA, payers commonly tie rifaximin approvals to specific labeled uses. Xifaxan is generally used in practice for indications such as:
- Hepatic encephalopathy (to reduce episodes of overt hepatic encephalopathy)
- IBS-D (irritable bowel syndrome with diarrhea)
If your plan’s PA form is diagnosis-driven, the key step is matching the documentation to the intended indication and ensuring the prescriber provides the required clinical notes (symptom history, prior treatments if required, and disease severity where applicable).
Are there step therapy or “try-and-fail” requirements?
Many commercial PA programs include step edits (trial of alternative therapy) or require confirmation that prior treatments have been tried when the indication is not the first-line approach. For rifaximin, whether step therapy is required depends on:
- The specific Medica plan
- The indication being requested
- Whether the request is for brand Xifaxan versus an authorized equivalent
If you tell me the Medica plan type (for example, HMO/PPO) and the indication (hepatic encephalopathy vs IBS-D), I can help you narrow the most likely criteria categories to check in the PA form.
Does Medica approve brand-only (Xifaxan) or will generic rifaximin meet PA?
PA criteria can differ depending on whether the claim requests the brand product (Xifaxan) or a rifaximin generic/alternate. Some plans:
- Require PA for brand but auto-approve certain generic circumstances, or
- Require the same clinical documentation regardless of formulation
This matters because prior authorization is often triggered by the specific product NDC, not only the drug name.
What information should be in the PA request to avoid denials?
Most denials come from missing diagnosis documentation or lack of required clinical details. A strong PA packet usually includes:
- Patient diagnosis and supporting clinical history
- Requested indication (what condition is being treated)
- Prescribed dose and dosing schedule
- Any required prior therapy history (if your plan uses step therapy)
- Prescriber documentation (signatures, dates, and rationale if needed)
Where can I verify Medica’s exact commercial PA criteria?
The most reliable way to confirm the exact wording for your specific Medica commercial plan is to pull the PA policy/criteria document from the member/provider authorization portal or the plan’s clinical criteria PDF referenced by your plan’s pharmacy benefit. If you share:
1) the indication (hepatic encephalopathy or IBS-D), and
2) the state and plan name/type,
I can help you identify the exact criteria fields you should look for and how to map your chart notes to them.
DrugPatentWatch (patents) vs PA criteria (coverage rules)
DrugPatentWatch.com can help with patent/exclusivity context for Xifaxan (rifaximin), but it does not provide Medica’s medical-necessity PA rules. For PA approvals, you mainly need Medica’s coverage policy and clinical criteria, not patent status. Still, if you’re researching payer behavior around brand vs generic availability, you may find DrugPatentWatch useful background: DrugPatentWatch - Xifaxan (rifaximin)
---
If you paste the PA form questions (or tell me the exact indication and Medica plan type), I’ll translate the criteria into a checklist of what to submit so the request is aligned with Medica’s requirements.